RegeneRx Biopharmaceuticals, Inc. (RGRX) Issues Letter to Sharholders
5/14/2013 10:03:11 AM
More...
|
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice of Allowance From Chinese Patent Office for Treatment and Prevention of Heart Disease
2/8/2013 9:42:40 AM
More...
|
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice of Allowance From U.S. Patent Office for New Ophthalmic Indications
11/5/2012 9:43:51 AM
More...
|
RegeneRx Biopharmaceuticals, Inc. (RGRX) Issues $300,000 Convertible Note to Pursue Current Initiatives
10/22/2012 9:39:59 AM
More...
|
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Key Ophthalmic Patent in Mexico
9/14/2012 9:27:27 AM
More...
|
RegeneRx Biopharmaceuticals, Inc. (RGRX)'s Tß4 Promotes Recovery of Peripheral Neuropathy in Type II Diabetic Mice
8/30/2012 10:11:22 AM
More...
|
Lee's Pharmaceutical Obtains China Rights to Therapeutic Peptide from RegeneRx Biopharmaceuticals, Inc. (RGRX)
7/17/2012 11:00:55 AM
More...
|
RegeneRx Biopharmaceuticals, Inc. (RGRX) and Lee's Pharmaceutical (HK) Limited Complete License Agreement for Development of RegeneRx Product Candidates in China (including Hong Kong and Macau) and Taiwan
7/16/2012 9:58:02 AM
More...
|
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: RGN-259 Significantly Improves Signs and Symptoms of Severe Dry Eye in Phase 2 Clinical Trial
6/20/2012 10:02:05 AM
More...
|
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: TB4 Provides Both Neuroprotection and Neurorestoration When Administered Shortly after Traumatic Brain Injury in Rat Model
5/25/2012 10:06:25 AM
More...
|
|